|Printable version||E-mail this to a friend|
Cancer Research UK - Tumour cells in blood samples could predict prostate cancer spread
Researchers have found a group of circulating tumour cells in prostate cancer patient blood samples which are linked to the spread of the disease, according to new research* presented at the National Cancer Research Institute (NCRI) Cancer Conference in Liverpool.
This is the first time these cell types have been shown to be a promising marker for prostate cancer spread.
In a study of around 80 samples from men with prostate cancer, scientists at the Barts Cancer Institute at Queen Mary University looked for cells that were gaining the ability to migrate and invade through the body.**
Samples with more of these cells were more likely to come from patients whose cancer had spread or was more aggressive.
This means that, in the future, these particular cells could potentially be used as a marker to monitor prostate cancer patients and predict if the disease is going to spread – alongside other monitoring techniques.
There are around 46,500 new cases of prostate cancer each year in the UK, and around 11,000 people die from the disease each year.
Dr Yong-Jie Lu, lead author from QMUL’s Barts Cancer Institute, said: “Our research shows that the number of these specific cells in a patient’s sample is a good indicator of prostate cancer spreading. By identifying these cells, which have gained the ability to move through the body, we have found a potential new way to monitor the disease.
“If we’re able to replicate these studies in larger groups of people, we may be able to one day predict the risk of someone’s cancer spreading so they can make more informed treatment decisions.”
Dr Chris Parker, Chair of the NCRI's Prostate Cancer Clinical Studies Group, said: “There’s a need to develop better tests to identify and monitor men with aggressive prostate cancer. This research has found a promising new marker that could one day make it to the clinic to guide treatment decisions.”
This research was funded by Orchid Cancer Appeal, ANGLE plc and Chinese Scholarship Council. The scientists used a highly innovative cell separation technology Parsortix™, developed by UK company ANGLE plc that is able to capture the circulating tumour cells.
Notes to Editor
* Abstract: Capture of circulating tumour cells with epithelial and mesenchymal features for prostate cancer prognosis
** This is known as epithelial to mesenchymal transition (EMT).
Latest News from
Age UK - Over half of lonely older people have never talked about it21/03/2017 13:35:00
Worrying figures revealed in Gransnet survey as the Jo Cox Commission on Loneliness launches its spotlight on older people month.
Cancer Research UK - Radiotherapy risks are much higher for smokers21/03/2017 12:35:00
Smokers treated for breast cancer have much higher risks than non-smokers of developing lung cancer or heart attack as a result of radiotherapy – according to a new study funded by Cancer Research UK and published yesterday in the Journal of Clinical Oncology
Age UK - Hike in calls to advice line over winter as more people seek help21/03/2017 08:35:00
Age UK saw a 12 per cent increase in calls to its national advice line from older people seeking help this winter compared to the same period last year, with enquiries about residential care the most frequent reason for getting in touch.
Cancer Research UK - 'Unacceptable' plans revealed by NICE that could delay availability of drugs on the NHS in England16/03/2017 11:35:00
Plans to create an additional affordability test for medicines available on the NHS have been labelled ‘unacceptable’ by charities and politicians.
Cancer Research UK to only contact supporters who have ‘opted in’ from 1 July 201715/03/2017 10:35:00
Cancer Research UK is to become an ‘opt in’ charity on 1 July 2017, meaning it will only contact supporters who have given unambiguous and explicit permission for the charity to contact them for marketing activity, including fundraising support.